The use of short-term hormone therapy for menopause is not associated with long-term cognitive impact after 10 years.

A conversation with Stacy Loeb, MD Professor of Urology and Population Health at NYU Langone Health and the Manhattan VA.

After skin cancer, prostate cancer is the most common cancer in men in the US. For the men who have beat prostate cancer once ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

New research from the IU School of Medicine found a discovery that could lead to new treatments for prostate cancer. The American Cancer Society said one in eight men will be ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

The University of Mississippi Medical Center Cancer Center and Research Institute received a $1.4 million grant from the U.S.

We conducted a narrative review of clinical trials focused on GU malignancy (prostate ... assess treatment burden across key domains including financial, time and travel, and medication management.

Proxalutamide (GT-0918) is under development for the treatment of Coronavirus COVID-19 disease, metastatic hormone-sensitive prostate cancer, hormone senstive, castration resistant prostate cancer ...

Compared to white men, Black men are at greater risk of prostate cancer, more likely to develop it earlier, and more likely to die from it. Earlier screening may be warranted. Dr. Sheel Patel ...